Evidence map›Paper›PMID 34962221›Full record

ArticleDrug delivery2022

Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control.

Marc Mac Giolla Eain, Ronan Cahill, Ronan MacLoughlin, Kevin Nolan

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Marc Mac Giolla EainAerogen Ltd, IDA Business Park, Galway, Ireland.
Ronan CahillSchool of Medicine, UCD Centre for Precision Surgery, University College Dublin, Dublin, Ireland.
Ronan MacLoughlinAerogen Ltd, IDA Business Park, Galway, Ireland.
Kevin NolanSchool of Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland.
Aerogen (Ireland) · IEUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy,

Indexed as

AerosolsCOVID-19Drug Delivery SystemsNebulizers and VaporizersRespiratory TherapyComputer SimulationEquipment DesignHumansInfection ControlInfectious Disease Transmission, Patient-to-ProfessionalModels, BiologicalParticle SizeSARS-CoV-2Aerosolsaerosol therapyaerosol visualizationCOVID-19fugitive emissionsSchlieren imagingvibrating mesh nebulizerviral infections

Identifiers

PMID34962221
PMCPMC8725970
OpenAlexW4225886606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.